GVK BIOSCIENCES

BY :P EY U S H KOU L
15020241084
MBA-IB B

COMPANY OVERVIEW
GVK
Bioscience
s (GVK
BIO) is one
of Asias
leading
Discovery
Research
and
Developm
ent
organisatio
GVKns.
BIOs
2400
employees
serve a
diverse
and global
customer
base of
more than
300
satisfied
customers.

GVK BIO
capabilitie
s include
Integrated
Programs,
Discovery
Services,
Clinical
Developm
ent,
Contract
Manufactur
ing,
Formulatio
ns and
Informatics
.

COMPANY PORTFOLIO
The companys registered corporate office is located in
Nacharam, Hyderabad.
The company has presence at two international locationsMassachusetts, USA and Amsterdam, Netherlands.
The company is not listed in any of the stock exchanges.
The company offers following services:
Discovery Services
Clinical Development
Formulations R&D and Manufacturing
API R&D and Manufacturing
Informatics and Analytics

COMPANY VALUES
VisionBe a global leader in life-sciences services.
MissionDeliver value-added scientific services with
speed and quality.
Values CIRCLe
Customer Focus Change expected to exceptional.

Integrity Integrity is integral.

Respect Give to get.
Commit to Excel In every act and deed.
Teamwork and Leadership Team first.

GVKS BIO EXPANSION STRATEGY

GVK Bio
acquired
Vanta
Bioscience

GVK Bio
acquires
6.12% of
Inogent
Laboratories

Horizontal
Integration
Acquisitions
Joint
Ventures

Swedish
PharmaMedivir
partners with
GVK Bio for
drug
research.

ANALYZING COMPANY STRATEGY

Acquisition of Vanta Bioscience
Business strategy to strengthen the portfolio of drug discovery
services.
To upgrade itself to provide world class R&D services.

Acquisition of Inogent from Dai-ichi Karkaria Ltd.

Horizontal integration to increase the volume of the company.
Strategy to increase market capitalization.

Partnership with Medivir Pharma

Knowledge sharing will accelerate the synthesis and testing of
compounds.
Opportunity to improve the quality and efficiency to global
standards.

CHALLENGES FACED BY COMPANY

French
regulator
ANSM
questioned
the quality of
some studies
done at GVK

Suspension of
market
authorization
of all drugs
tested by
GVK between
2008-14

Huge losses
in revenue
due to
distrust in
quality
standards.

Legal
Hurdles.